Vivant Reports 1H2026 Core Net Income Of PHP784 Million As Power Generation Remains The Largest Contributor While Share Of Water Business Grows

Vivant Corporation posted PHP784 million in core net income for the first half of 2026, with power generation remaining its largest earnings contributor.

Pag-IBIG Fund Net Income Up 24% To PHP41.35 Billion In First Half Of 2026

Pag-IBIG Fund posts record first-half net income of PHP41.35 billion, reflecting stronger earnings and disciplined cost management.

Borromeo Motoring Group Signs New RES Deal For 20 Luzon Dealerships

Borromeo Motoring Group taps COREnergy to manage power more strategically across 20 Luzon dealerships and automotive facilities.

Two Founders, One Purpose: How Joel Cabugos And Jax Reyes Built KasKasan Buddies

KasKasan Buddies grew from the complementary strengths of Joel Cabugos and Jax Reyes, whose shared vision placed financial education and community value at the center.

Delivery Of 30M Covovax Doses To PH Starts In Q3 Of 2021

The delivery of 30 million doses of the COVID-19 vaccine Covovax will start in July. Magpapabakuna ka ba?

Delivery Of 30M Covovax Doses To PH Starts In Q3 Of 2021

104
104

How do you feel about this story?

Express Your Reaction
Like
Love
Haha
Wow
Sad
Angry

The delivery of 30 million doses of the Covid-19 vaccine Covovax to the country will begin in the third quarter of the year, Fabreco Life Institutes Medical Director Dr. Luningning Villa said on Monday.

In virtual Palace presser, Villa said the delivery will start “within” July, August and September.

“More or less five to six months, matagal na po siguro ‘yung six months na makumpleto po iyong (six months would be the maximum period to complete the) delivery,” Villa added.

Fabreco Life Institutes is the local partner of Serum Institute of India (SII) which is the world’s largest vaccine manufacturer.

SII and Novavax, a US-based biotechnology company, have partnered to develop and commercialize the Covovax vaccine.

Through vaccine czar Carlito Galvez Jr., the government has signed a term sheet for the supply of the 30 million Covavax vaccine doses.

Covavax is in Phase 3 clinical trials and is expected to be approved for use by international regulators.

“We hope to have the EUA (emergency use authorization). Most likely, the United Kingdom will go first because they will finish the clinical trial first,” Villa said. “And of course, with that, with the results of the Phase 3, we’ll have hopefully EUA here in the Philippines by the FDA (Food and Drug Administration), of course with their evaluation.”

Covovax, Villa noted, is stable at 2°C to 8°C which is the standard temperature that is within the existing cold chain system in the country.

“Kahit doon sa malalayong baranggay na may health facility na magkakaroon ng vaccination, kayang-kaya po, stable pa rin po ang Covavax (Even if in the remotest barangays with health facility that will have vaccination, it can be used, the Covavax is still stable),” she said.

Apart from Covavax, the country has also secured 25 million doses of Sinovac vaccines and 2.6 million doses of vaccine from AstraZeneca which are expected to arrive in the second quarter of the year.

During the same Palace briefing, Presidential Spokesperson Harry Roque said the first 50,000 doses of China’s Sinovac vaccine will arrive in February aside from 15,000 doses to be used for clinical trials in the country.

“At least, by February, 65,000 na ang mabibigyan ng bakuna (But at least, 65,000 will be inoculated by February),” he said.

He said the delivery of 25 million doses of Sinovac vaccines is expected to be completed by December this year.

The government has also been negotiating other pharmaceutical companies including Pfizer, Johnson & Johnson, and Gamaleya Institute. (PNA)